Dyerberg J, Jørgensen K A
Artery. 1980;8(1):12-7.
All cis-5,8,11,14,17 eicosapentaenoic acid (EPA) inhibits platelet aggregation. The mechanisms for this inhibition are not known in detail. One of them might be a competitive inhibition of TXA2 production. Even if rat and human vasculature in pure systems covert EPA to PGI3 with the same properties as PGI2, it is essential to known if EPA influences the conversion of arachidonic acid (AA) to PGI2 in human vasculature. This problem was investigated in human umbilical vascular tissue deprived of substrate for PGI synthesis. After incubation with AA or EPA alone and in combinations, prostacyclin synthesis was measured as PGI2. Prostacyclin production in assays with AA and EPA in combinations in the incubation mixture, was found additive as calculated from assays with pure substrates. Thus, EPA did not influence the conversion of AA to PGI2 but gave obviously rise to additional synthesis of PGI-like material.
所有顺式-5,8,11,14,17-二十碳五烯酸(EPA)均抑制血小板聚集。这种抑制的机制尚不完全清楚。其中之一可能是对血栓素A2生成的竞争性抑制。即使在纯系统中大鼠和人类血管将EPA转化为具有与前列环素(PGI2)相同特性的前列环素(PGI3),了解EPA是否会影响人类血管中花生四烯酸(AA)向PGI2的转化也至关重要。在缺乏PGI合成底物的人脐血管组织中对该问题进行了研究。单独及联合使用AA或EPA孵育后,以前列环素(PGI2)的形式测量前列环素的合成。根据纯底物测定计算,孵育混合物中联合使用AA和EPA的测定中前列环素的产生是相加的。因此,EPA不影响AA向PGI2的转化,但明显导致了类似PGI物质的额外合成。